Giant Cell Tumor of the Phalanx of Finger: Case Reports by Utomo, Pamudji et al.
Indonesian Journal of Medicine (2019), 4(1): 65-74 
https://doi.org/10.26911/theijmed.2019.04.01.11 
e-ISSN: 2549-0265  65 
Giant Cell Tumor of the Phalanx of Finger: Case Reports 
 
Pamudji Utomo1), Mujaddid Idulhaq1), Ambar Mudigdo2, 
Okkie Mharga Sentana1) 
 
1)Department of Orthopaedic and Traumatology, Prof. Dr. R. Soeharso 
Orthopaedics Hospital/Faculty of Medicine, Universitas Sebelas Maret 
2)Department of Pathology and Anatomy, Faculty of Medicine, 




Background: Giant cell tumor (GCT) of bone arising from aphalanx of finger is extremely rare. 
Although, the occurrence of GCT in the hands is a rare, it has been reported that GCT of the small 
bones (small-bone GCT) carries a higher risk of local recurrence and metastasis than conventional 
GCT.  
Subjects and Method: We report two cases of GCT arising from a phalanx of a hand finger. First 
patient was treated with wide excision of the tumor and fusion with fibular bone graft with the help 
of a K-wire. Second patient was treated by excision of tumour (Curretage) with allograft bonegraft 
for bone defect.  
Results: At their most recent follow-ups (4 months, respectively), both were recurrence free and 
had returned to their previous occupational and recreational activities. 
Conclusion: The effectiveness of these methods in the treatment and prevention of recurrence is 
still under discussion and there is no gold standard for treating GCT. 
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BACKGROUND 
Giant cell tumour (GCT) in bone is usually 
located in the ends of the long bone, 
accounting for approximately for 5% of 
primary bone tumour. Only 2-5% of GCTs 
are located in the hand. (Athanasian et al., 
1997; Averill et al., 1980; Yanagisawa et al., 
2011). Giant cell tumor is commonly seen in 
the epi-metaphyseal ends of long bones in 
young adults (Frassica et al., 1993). In the 
hand region, GCTs are primarily located in 
the metacarpal bones; second, they are 
located in the phalanges and, rarely, they 
are located within the thumb (Reichert et 
al., 2017). 
Giant celltumor of bone (GCT) is a 
benign aggressive, locally recurrenttumor 
with a low  metastatic potential (4%-8%) 
(Malawer et al., 2012). 
The natural history of GCTs varies 
widely and can range from local bony 
destruction to local metastasis, metastasis 
to the lung, metastasis to lymph nodes, or 
malignant transformation (Moon et al., 
2012). 
Although, the occurrence of GCT in 
the hands is a rare, it has been reported 
that GCT of the small bones (small-bone 
GCT) carries a higher risk of local recur-
rence and metastasis than conventional 
GCT. The treatment of GCT using intra-
regional procedures includes the following: 
curettage and bone grafting or excisional 
procedures, such as local excision, wide 
excision, amputation, and ray resection.1 
Intralesional curettage may be improved 
with local adjuvant treatment, such as 
phenol (Becker et al., 2008; Trieb et al., 
Utomo et al./ Giant Cell Tumor of the Phalanx of Finger 
66   e-ISSN: 2549-0265 
2001) alcohol, (Errani et al., 2010; Jones et 
al., 2006), and cryotherapy (Marcove et al., 
1978; Malawer et al., 1999). Bone defects 
can be supplemented with polymethyl-
methacrylate (PMMA) cement, autograft, 
allograft, or bone substitute (Algawahmed 
et al., 2010). In addition, treatment can be 
enhanced with the use of monoclonal 
antibody (Thomas et al., 2010), calcitonin 
(Nouri et al., 2011), and bisphosphonates 
(Balke et al., 2010). 
Here, we report two case of GCT 
phalanx of finger that had been treated with 
wide excision and reconstruction with 
fibular graft and the other case with 




A 54 year old Female presented with swell-
ing of the index finger of dominant right 
hand since one and a half years ago. On 
careful history taking and review of old 
record, one and a half years ago her index 
finger was squezzed at the window and 
become swelling until now. 5 months before 
admission, she came at other hospital with 
the same swelling which was however 
smaller in size and had been performed 
open biopsy with the result is Giant cell 
tumour. But after that, she did not report 
back and over the time the swelling had 
increased in size. There was not any pain or 
night pain over her index finger. From 
physical examination, there was lump with 
size 5x4x3 cm, ulcer, and swelling over her 
index finger. This lump was palpable solid, 
fixated, with irreguler and strict line border. 
At our center, we did his blood 
examination for hemoglobin, C-reactive 
protein, and erythrocyte sedimentation 
rate. Total and differential leukocyte counts 
and serum alkaline phosphatase levels 
which were within normal range. Radio-
graph showed expansile lytic lesion,with 
irregular sclerotic margin, cortical breach, 
extensive soft tissue extension, and com-
plete destruction of the proximal phalanx of 
indexfinger. First open biopsy was sugges-
tive of giant cell tumour. MRI showed a 
hypointense signal in the T1 W sequences 
and heterogeneously hyperintense signal in 
the T2 W and PD sequences with extensive 

















Figure 1. Clinical Picture of 2nd finger of the right hand 
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Figure 2. X-Ray and MRI of the 2nd finger of the right hand 
 
Ultimately a diagnosis of Campanacci 
Grade III GCT of the proximal phalanx of 
index finger was made. After counseling the 
patient about the likelihood of a repeat 
recurrence and chances of local complica-
tions at the finger in the form of gangrene, 
infection, nonhealing of reconstruct, and 
recurrence, the patient was treated with 
wide excision of the proximal phalanx and 
fusion with fibular bone graft with the help 
of a K-wire. Histopathological examination 
reconfirmed that it was a giant cell tumor. 
On 6 month follow-up, his wound had 
















Figure 3. Excision of the mass and Fibular graft 
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Figure 4. X-Ray post operative and follow up for 6 month 
 
CASE 2 
A 15-year-old boy presented with a five-
month history of increasing swelling and 
pain in the fourth middle phalanx of his left 
hand with history of trauma, his ring finger 
hit by volley ball 6 month ago. In physical 
examination, there was a palpable, firm, 
and non-mobile 2 × 1x 1cm mass. The mass 
has been progressively growing with a 
natural pain. Proximal interphalengeal pha-
lanx and metacarpophalengeal joints 
motion was impaired (Figure 5). 
Primary laboratory tests including cell 
blood count, ESR, and CRP were normal. 
Radiographs showed an expansive mixed 
lytic-blastic lesion of middle of the fourth 
phalanx bone with cortical destruction and 
soft tissue involvement. For the CT-Scan, 
there was lusen and septum lesion, expan-
sile at metaphyseal region of the middle 
phalanx of fourth finger. It suggest Aneu-
rysma Bone Cyst with differential diagnose 

















Figure 5. Clinical Picture of 4th finger of right hand 
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Figure 6. CT-Scan of the 4th finger of right hand 
 
Ultimately a diagnosis of Campanacci 
Grade III GCT of the proximal phalanx of 
index finger was made. After counseling the 
patient, complete excision of tumour 
(Curretage) with allograft bonegraft for 
bone defect was done. The tumour sent for 
histopathology. The histopathology con-
firmed the diagnosis of giant cell tumor 
with showed a benign tumour composed of 
small mononuclear cells which are round 
and spindle shape with pale cytoplasm and 
round nuclei along with osteoclast-like 
giant cells. Follow-up in the six months 
post operative day, has been satisfactory 
and patient informed of the need for follow 













Figure 7. Curretage-bonegraft and X-ray Post Operation 
Utomo et al./ Giant Cell Tumor of the Phalanx of Finger 




















Figure 8. Follow up for 6 month 
 
DISCUSSION 
GCT of the hand is rare and is different 
from conventional GCT as recurrence is 
more common in the hand (Saikia et al., 
2009). It is even rarer to encounter a GCT 
arising from the phalanges. More than 
2,400 skeletal GCTs were reported in the 
literature, but not even 50 were found to be 
in the phalanges of the hand (Patel et al., 
1987; Saikia et al., 2009; Bloodgood, 1919; 
Coley et al., 1958) reported only two cases 
of GCT arising from the phalanges in their 
series of 108 cases.  
Goldenberg et al., (1970) in their ana-
lysis of 218 cases of GCT, reported six cases 
involving the phalanges. In another two 
large series of 568 and 327 cases of GCT, 
authors found only four and one cases of 
phalangeal involvement, respectively (Dah-
lin, 1996; Campanacci et al., 1987; Yasuda 
et al, 2008) reported a multicentric GCT of 
the hand involving a finger and the wrist. 
Benign metastasizing GCT of the hand has 
also been reported (Lopez Barea et al., 
1992). 
Giant cell tumors are generally consi-
dered benign, locally aggressive bone 
tumors. They may metastasize in up to 10% 
of patients, but usually do so only after 
repetitive local recurrences. When they 
occur in the hand they frequently cause 
severe bony destruction and extend into the 
surrounding soft tissues.  
Primary Giant cell tumour involving 
the bones of the hand were occupying 
central location, expansile with paper-thin 
cortex, which differs from the usual 
eccentric location seen in Giant cell tumour 
of bones at other sites. GCT of bone hands 
is considered more aggressive, with higher 
rate of recurrence than other skeletal sites 
(Minhas, 2010). Historically, the major 
problem with treating giant cell tumors of 
the hand has been achieving local tumor 
control without the need for radical resect-
ion or amputation (Wittig et al., 2001). 
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On plain radiographs, GCT almost 
invariably presents as a geographic lytic 
lesion with a well-defined, non-sclerotic 
margin (80%–85% of cases). As with other 
musculoskeletal neoplasms, CT and MR 
imaging allow superior delineation and 
local staging of GCTs. CT is particularly 
useful for the identification of cortical 
thinning, pathologic fracture, periosteal 
reaction, assessing the degree of osseous 
expansile remodelling, and confirming the 
absence of matrix mineralization. CT is 
generally superior to MR imaging in assess-
ing these features. MR imaging frequently 
reveals a relatively well-defined lesion with 
a low-signal-intensity margin, representing 
either osseous sclerosis or a pseudocapsule. 
the solid components of GCT show a low to 
intermediate signal intensity at T1- and 
nonfat-suppressed T2-weighted MR 
imaging. Bone scintigraphy demonstrates 
increased radionuclide uptake in the vast 
majority of GCTs, Increased radionuclide 
uptake peripherally with photopenia cen-
trally, termed the “donut sign,” was seen in 
57% of cases ( Dasan et al., 2012). 
GCT was originally thought to be a 
type of osteosarcoma. Some authors have 
reported that the diagnosis could be made 
by excluding other possibilities. The radio-
logic differential diagnosis for such lesion 
includes aneurysmal bone cysts, benign 
chondroblastoma, non-osteogenic fibroma, 
simple bone cyst, and, in some cases, osteo-
sarcoma, brown tumour of hyperparathy-
roidism, enchondroma, metastatic disease, 
chondrosarcoma, and giant cell reparative 
granuloma.(Dahlin DC, 1985) GCT in the 
hand is well characterised and has a higher 
risk of malignancy, recurrence and meta-
static disease. 
In this case, retaining function of the 
thumb with sufficiently aggressive surgical 
treatment is extremely difficult (Fnini et al., 
2008). The treatment of GCT using intra-
regional procedures includes the following: 
curettage and bone grafting or excisional 
procedures, such as local excision, wide 
excision, amputation, and ray resection.1 
Intralesional curettage may be improved 
with local adjuvant treatment, such as 
phenol (Becker et al., 2008; Trieb et al., 
2001), alcohol (Errani et al., 2010; Jones et 
al., 2006), and cryotherapy (Marcove et al., 
1978; Malawer et al., 1999). Bone defects 
can be supplemented with polymethyl-
methacrylate (PMMA) cement, autograft, 
allograft or bone substitute (Algawahmed et 
al., 2010). 
In addition, treatment can be enhan-
ced with the use of monoclonal antibody 
(Thomas et al., 2010) calcitonin (Nouri et 
al., 2011) and bisphosphonates (Balke et al., 
2010). However, it should be noted that the 
effectiveness of these methods in the 
treatment and prevention of recurrence is 
still under discussion and there is no gold 
standard for treating GCT (Reichert et al., 
2017). 
Procedures such as curettage and 
bone grafting do not give satisfactory 
results and may contribute to recurrence. 
Due to the high percentage of recurrence, 
some authors do not recommend curettage 
alone.(Athanasian et al., 1997; Averill et al., 
1980). Averill et al. (1980) reported success 
in more than 70% of recurrent lesions that 
were treated with wide excision or amputa-
tion (Dickson et al., 2008; Averill et al., 
1980).  
On the other hand, an amputation or 
ray resection isassociated with loss of motor 
function and various degrees of injury to 
the patient. Due to the lack of satisfactory 
outcomes, a number of authors are trying to 
determine the risk factors that affect the 
number of relapses (Dickson et al, 2008; 
Williams et al., 2010) reported on the 
expression of p63 immunostaining in the 
mononuclear cells of giant cell tumours. 
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(Dickson et al., 2008). This examination is 
useful for distinguishing between giant cell 
tumour and other giant cell-rich tumours, 
such as aneurysmal bone cysts, chondro-
blastoma, and reparative giant cell granu-
loma. On the other hand, Williams showed 
no significance for gender, age, hand domi-
nance or radiologic findings (Williams et 
al., 2010). The statistical analysis showed 
significant differences between specific 
tissue or expires and recurrence. Positive 
correlation was noted for involvement of 
the extensor tendon, flexor tendon, and join 
capsule. 
Evaluation of the treatment outcomes 
was confounded by the fact that although 
most recurrences occur within 3 years of 
treatment, late recurrence of giant cell 
tumours, even after 15 years later, have 
been observed in the location where iden-
tified lesion had been surgically managed 
(Scully et al., 1994), others were observed 
to recur as late as 42 years later (Golden-
berg et al., 1970). 
One reason for the high number of 
recurrences is insufficient removal of radi-
cal changes during curettage. When using 
curettage, we cannot assess whether the 
tumour has been fully removed. Moreover, 
any recurrence that is combined with 
involvement of another bone region, as in 
the case of the thumb, restricts the subse-
quent procedure options. The histopatho-
logical confirmation of a safely excised 
margin offers the best chance for avoiding 
recurrence. An additional advantage of a 
two-stage treatment is avoidance of an 
incorrect diagnosis because the results do 
not always coincide with the biopsy results. 
Additionally, in the event of misdiagnosis, 
this approach allows for the use of different 
treatment techniques (Reichert et al., 
2017). 
In our cases, we still doing limb sal-
vage surgery with wide excision or curre-
tage and also reconstruction with allograft 
or autograft with fibular graft. Misdiagnosis 
and resection of the tumour with too small 
of a safety margin contributes to recurrence 
and requires changing the procedure to a 
more invasive technique. The histopatho-
logical confirmation of dianosis and radical 
removal of the tumour increase the proba-
bility that there will not be any recurrence. 
 
CONCLUSION 
Giant cell tumors (GCT) of hand showed 
that primary Giant cell tumours involving 
bones of the hand are rare lesions which are 
generally diagnosed at an advanced stage. It 
should be noted that the effectiveness of 
these methods in the treatment and pre-
vention of recurrence is still under dis-
cussion and there is no gold standard for 
treating GCT. 
Misdiagnosis and resection of the 
tumour with too small of a safety margin 
contributes to recurrence and requires 
changing the procedure to a more invasive 
technique. The histopathological confirma-
tion of diagnosis and radical removal of the 
tumour increase the probability that there 
will not be any recurrence. 
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